Metabolic Fate of Hallucinogenic NBOMes
Identification of the metabolite(s) of the novel psychedelic 25B-NBOMe was approached using the following techniques: In vitro degradation was evaluated via incubation with porcine and human liver microsomes. The identities of the produced phase I metabolites were identified via LC-MS and by comparison with synthetic samples. Subsequently, the in vivo metabolism in pigs was investigated via injection of a pharmacological dose of 25B-NBOMe followed by LC-MS/MS analysis of blood samples to identify phase II metabolites. Structural assignment was again verified by comparison with authentic samples. [11C]- labeling of 25B-NBOMe in various positions and administering these [11C]-ligands to pigs and humans, followed by HPLC analysis of blood samples using a radiodetector, corroborated our structural assignment. Finally the main phase-I and phase-II metabolites were evaluated in the drug induced mouse head twitch response – a model that is predictive of hallucinogenic effects in man.
I am graduate student at the University of Copenhagen, working towards the development of orally available and selective serotonin 2A receptor agonists. I am trained as a medicinal chemist, including six months doing medicinal chemistry research under the guidance of Professor David E. Nichols at Purdue University, and 16 months at H. Lundbeck A/S. In addition to this I have been trained in pharmacology, including six months in the laboratory of Dr. William E. Fantegrossi at the University of Arkansas for Medical Sciences, testing novel compounds in mouse models relevant to hallucinogens.